Nuvectis Pharma, Inc. — Form 10-Q
Filed August 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
Ron Bentsur (CEO/Chairman) and Michael J. Carson (VP Finance) signed standard Sarbanes-Oxley Section 302 and 906 certifications for the Q2 2026 10-Q filed August 4, 2026. Both officers certify the report contains no untrue material statements, financial statements fairly present the company's condition, and internal controls and disclosure procedures are effective. No specific business events, transactions, dollar amounts, or material changes are disclosed in these certification exhibits.
Why this rating
Routine SOX certification exhibits; purely compliance boilerplate. No material business event, transaction, or disclosure change described.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.